46
MEDYA
TR
EN
Home
Genel
News Detail
Morning Star
May 28, 2026
|
19:00
Draig Therapeutics Presents New Phase 1 Data Demonstrating Safety, Tolerability, Pulsatile PK and Target Engagement by DT-101, a Novel AMPA Receptor Potentiator, at ASCP Annual Meeting
...
Full Story at Source
Related News
Cornerstone Building Brands Strengthens Mueller™ Retail Network Through Fortify Building Solutions™ Rebrand and New Store Openings
AM Best to Sponsor, Exhibit at Insurance Council of New Zealand’s 2026 Conference
Harvest ETFs announces Final May 2026 Cash Distribution for the Harvest Canadian T-Bill ETF
Deadline Soon: Pinterest, Inc. (PINS) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
